```
=> e piperidine/cn
E1            1     PIPERIDINAMINE, N-((3,4-DIMETHOXYPHENYL)METHYL)-/CN
E2            1     PIPERIDINAMINE, POLYMER WITH (CHLOROMETHYL)OXIRANE AND 4,4'-
                    (1-METHYLETHYLIDENE)BIS(PHENOL)/CN
E3            1 --> PIPERIDINE/CN
E4            1     PIPERIDINE 1,2-CYCLOBUTANE DICARBOXYLATE/CN
E5            1     PIPERIDINE 1,2-CYCLOHEXANEDICARBOXYLATE/CN
E6            1     PIPERIDINE 1,2-CYCLOPENTANE DICARBOXYLATE/CN
E7            1     PIPERIDINE 1,2-CYCLOPROPANE DICARBOXYLATE/CN
E8            1     PIPERIDINE 183A/CN
E9            1     PIPERIDINE 2,4,6-TRINITROPHENOLATE/CN
E10           1     PIPERIDINE 2,4-DINITROPHENOLATE/CN
E11           1     PIPERIDINE 207E/CN
E12           1     PIPERIDINE 211B/CN

=> s e3
L1            1 PIPERIDINE/CN

=> d str rsd

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
```


```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


Ring System Data

Elemental|Elemental| Size of |Ring System|   Ring    |   RID
Analysis |Sequence |the Rings|  Formula  |Identifier|Occurrence
   EA    |   ES    |   SZ    |    RF     |   RID    |  Count
=========+=========+=========+===========+==========+==========
C5N      |NC5      |6        |C5N        |46.156.1  |1




=> e indole/cn
E1            1     INDOLAPRILAT/CN
E2            1     INDOLBI/CN
E3            1 --> INDOLE/CN
E4            1     INDOLE 2,3-DIOXYGENASE/CN
E5            1     INDOLE 3-ACETONITRILASE/CN
E6            1     INDOLE 3-ACETYLASPARTATE HYDROLYASE/CN
E7            1     INDOLE 3-HYDROXYLASE/CN
E8            1     INDOLE ACETAMIDE HYDROLASE (AGROBACTERIUM TUMEFACIENS STRAIN
                    C58 GENE TMS2)/CN
E9            1     INDOLE ACETAMIDE HYDROLASE (AZOARCUS STRAIN BH72 GENE TMS)/C
                    N
E10           1     INDOLE ACETAMIDE HYDROLASE (BRADYRHIZOBIUM JAPONICUM STRAIN
                    USDA110 GENE TMS2)/CN
E11           1     INDOLE ACETAMIDE HYDROLASE (BURKHOLDERIA PSEUDOMALLEI STRAIN
                    K96243)/CN
E12           1     INDOLE ACETAMIDE HYDROLASE (BURKHOLDERIA XENOVORANS STRAIN L
```

B400)/CN

```
=> s e3
L2             1 INDOLE/CN

=> d str rsd

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
```

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Ring System Data

Elemental Analysis EA	Elemental Sequence ES	Size of the Rings SZ	Ring System Formula RF	Ring Identifier RID	RID Occurrence Count
C4N-C6	NC4-C6	5-6	C8N	333.151.57	1

```
     FILE 'REGISTRY' ENTERED AT 07:16:00 ON 28 MAY 2009
                  E PIPERIDINE/CN
L1             1 S E3
                  E INDOLE/CN
L2             1 S E3
L3        210333 S 46.156/RID (P) 333.151/RID
L4                STRUC
L5            18 SEARCH L4 SSS  SUB=L3 SAMPLE

=> d 14
L4 HAS NO ANSWERS
L4                STR
```




```
VAR G1=8/7/12/11
VPA 16-1/2/3 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   7   3
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE


=> search 14
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:l3
'L3' IS NOT A VALID SEARCH SCOPE
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:end
SEARCH ENDED BY USER

=> search 14
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
ENTER SUBSET L# OR (END):13
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
FULL SUBSET SEARCH INITIATED 07:24:35 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -   207321 TO ITERATE

100.0% PROCESSED   207321 ITERATIONS                          3811 ANSWERS
SEARCH TIME: 00.00.05

L6         3811 SEA SUB=L3 SSS FUL L4

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              217.04     217.26
```

FILE 'CAPLUS' ENTERED AT 07:24:46 ON 28 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 May 2009 VOL 150 ISS 22
FILE LAST UPDATED: 27 May 2009 (20090527/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate

```
=> s l6
L7          169 L6

=> s l7 and 5ht?
           9349 5HT?
L8            8 L7 AND 5HT?

=> d bib hitstr 8

L8   ANSWER 8 OF 8  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   1998:682229  CAPLUS
DN   129:302552
OREF 129:61715a,61718a
TI   Preparation of 1,4-disubstituted cyclic amine derivatives as serotonin
     antagonists
IN   Kitazawa, Noritaka; Ueno, Kohshi; Takahashi, Keiko; Kimura, Teiji; Sasaki,
     Atsushi; Kawano, Koki; Okabe, Tadashi; Komatsu, Makoto; Matsunaga, Manabu;
     Kubota, Atsuhiko
PA   Eisai Co., Ltd., Japan
SO   PCT Int. Appl., 635 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 9843956          A1     19981008    WO 1998-JP1481         19980331
         W:  AU, CA, CN, HU, JP, KR, MX, NO, NZ, RU, US
         RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     TW 242011           B      20051021    TW 1998-87104733       19980330
     CA 2280753          A1     19981008    CA 1998-2280753        19980331
```

	CA 2280753	C	20071204		
	AU 9865209	A	19981022	AU 1998-65209	19980331
	AU 748038	B2	20020530		
	ZA 9802707	A	19991020	ZA 1998-2707	19980331
	EP 976732	A1	20000202	EP 1998-911137	19980331
	EP 976732	B1	20041124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	HU 2000000434	A2	20000628	HU 2000-434	19980331
	HU 2000000434	A3	20020528		
	NZ 337651	A	20020426	NZ 1998-337651	19980331
	RU 2203275	C2	20030427	RU 1999-123039	19980331
	AT 283259	T	20041215	AT 1998-911137	19980331
	ES 2230681	T3	20050501	ES 1998-911137	19980331
	CN 1204121	C	20050601	CN 1998-803861	19980331
	JP 3953115	B1	20070808	JP 1998-541460	19980331
	US 6448243	B1	20020910	US 1999-367227	19990811
	NO 9904720	A	19991130	NO 1999-4720	19990928
	NO 314543	B1	20030407		
	HK 1026700	A1	20050826	HK 2000-105871	20000919
	US 20020086999	A1	20020704	US 2001-846259	20010502
	US 7071201	B2	20060704		
	US 20020019531	A1	20020214	US 2001-859517	20010518
	US 6579881	B2	20030617		
PRAI	JP 1997-98433	A	19970331		
	JP 1997-366764	A	19971226		
	WO 1998-JP1481	W	19980331		
	US 1999-367227	A3	19990811		

OS MARPAT 129:302552

IT 214611-86-6P 214611-87-7P 214611-88-8P
214611-89-9P 214616-51-0P 214616-52-1P
214616-53-2P 214616-54-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,4-disubstituted cyclic amine derivs. as serotonin antagonists)

RN 214611-86-6 CAPLUS

CN 1H-Indole, 1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-6-(4-piperidinylmethyl)- (CA INDEX NAME)



RN 214611-87-7 CAPLUS

CN Ethanone, 1-[4-[[1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-1H-indol-6-yl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 214611-88-8 CAPLUS

CN 1H-Indole, 6-[(1-ethyl-4-piperidinyl)methyl]-1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro- (CA INDEX NAME)



RN 214611-89-9 CAPLUS
CN 1H-Indole, 1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-6-[(1-methyl-4-piperidinyl)methyl]- (CA INDEX NAME)



RN 214616-51-0 CAPLUS
CN 1H-Indole, 1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-6-(4-piperidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 214616-52-1 CAPLUS
CN Ethanone, 1-[4-[[1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-1H-indol-6-yl]methyl]-1-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 214616-53-2 CAPLUS
CN 1H-Indole, 6-[(1-ethyl-4-piperidinyl)methyl]-1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-, monohydrochloride (9CI)

(CA INDEX NAME)



● HCl

RN 214616-54-3 CAPLUS
CN 1H-Indole, 1-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro-6-[(1-methyl-4-piperidinyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 7

L8 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:832788 CAPLUS
DN 137:337885
TI Preparation of heterocyclyloxy-, heterocyclylthioxy- and heterocyclylaminobenzazoles as 5-hydroxytryptamine-6 (5-HT6) ligands
IN Zhou, Ping; Harrison, Boyd Lynn; Li, Yanfang
PA Wyeth, John, and Brother Ltd., USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002085892	A1	20021031	WO 2002-US12415	20020419
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CA 2444095	A1	20021031	CA 2002-2444095	20020419
	AU 2002307424	A1	20021105	AU 2002-307424	20020419
	US 20030069278	A1	20030410	US 2002-126598	20020419
	US 6815456	B2	20041109		
	EP 1385842	A1	20040204	EP 2002-764248	20020419
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 2003003958	A2	20040428	HU 2003-3958	20020419
	CN 1518547	A	20040804	CN 2002-812308	20020419
	CN 1293072	C	20070103		
	BR 2002009056	A	20040810	BR 2002-9056	20020419
	JP 2004526787	T	20040902	JP 2002-583419	20020419
	IN 2003KN01264	A	20060310	IN 2003-KN1264	20031006
	MX 2003009476	A	20040212	MX 2003-9476	20031016
	NO 2003004648	A	20031120	NO 2003-4648	20031017
	ZA 2003009004	A	20050221	ZA 2003-9004	20031119
	US 20050065186	A1	20050324	US 2004-949062	20040924
	AU 2008203389	A1	20080821	AU 2008-203389	20080729
PRAI	US 2001-285643P	P	20010420		
	AU 2002-307424	A3	20020419		
	US 2002-126598	A3	20020419		
	WO 2002-US12415	W	20020419		

OS MARPAT 137:337885

IT 474002-60-3P 474002-62-5P 474003-38-8P
474003-40-2P 474003-42-4P 474003-44-6P
474003-46-8P 474003-48-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclyloxy-, heterocyclylthioxy- and heterocyclylaminobenzazoles as 5-hydroxytryptamine-6 (5-HT6) ligands)

RN 474002-60-3 CAPLUS

CN Benzenamine, 4-[[4-(4-piperidinyloxy)-1H-indol-1-yl]sulfonyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 474002-62-5 CAPLUS

CN Benzenamine, 4-[[4-(3-piperidinyloxy)-1H-indol-1-yl]sulfonyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 474003-38-8 CAPLUS
CN 1H-Indole, 1-(phenylsulfonyl)-4-(3-piperidinyloxy)- (CA INDEX NAME)



RN 474003-40-2 CAPLUS
CN Benzenamine, 4-[[4-(3-piperidinyloxy)-1H-indol-1-yl]sulfonyl]- (CA INDEX NAME)



RN 474003-42-4 CAPLUS
CN 1H-Indole, 1-(1-naphthalenylsulfonyl)-4-(3-piperidinyloxy)- (CA INDEX NAME)



RN 474003-44-6 CAPLUS
CN 1H-Indole, 1-(phenylsulfonyl)-4-(4-piperidinyloxy)- (CA INDEX NAME)



RN 474003-46-8 CAPLUS
CN Benzenamine, 4-[[4-(4-piperidinyloxy)-1H-indol-1-yl]sulfonyl]- (CA INDEX NAME)



RN 474003-48-0 CAPLUS
CN 1H-Indole, 1-(1-naphthalenylsulfonyl)-4-(4-piperidinyloxy)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 6

L8 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:656767 CAPLUS
DN 139:197493
TI Preparation of heterocyclic compounds possessing affinity at 5-HT1-type receptors and uses thereof in therapy
IN Harrington, Frank Peter; Smith, Paul William; Ward, Simon E.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068772	A1	20030821	WO 2003-EP1711	20030217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003212254	A1	20030904	AU 2003-212254	20030217
	EP 1476444	A1	20041117	EP 2003-708113	20030217
	EP 1476444	B1	20060412		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005527500	T	20050915	JP 2003-567899	20030217
	AT 323085	T	20060415	AT 2003-708113	20030217
	ES 2259759	T3	20061016	ES 2003-708113	20030217
	US 20050085458	A1	20050421	US 2004-504109	20040810
	US 7244726	B2	20070717		
PRAI	GB 2002-3804	A	20020218		
	WO 2003-EP1711	W	20030217		

OS MARPAT 139:197493
IT 583031-40-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of piperidinyl/piperazinylalkyl substituted benzoxazines as ligands for 5-HT1A, 5-HT1B and 5-HT1D receptors and uses thereof)

RN 583031-40-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-[[1-[2-[(2-methyl-5-quinolinyl)oxy]ethyl]-4-piperidinylidene]methyl]- (CA INDEX NAME)



IT 583031-41-8P, 6-[1-[2-((2-Methylquinolin-5-yl)oxy)ethyl]piperidin-4-ylmethyl]-1,3-dihydroindol-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinyl/piperazinylalkyl substituted benzoxazines as ligands for 5-HT1A, 5-HT1B and 5-HT1D receptors and uses thereof)

RN 583031-41-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-[[1-[2-[(2-methyl-5-quinolinyl)oxy]ethyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



IT 583031-25-8P, 6-(Piperidin-4-ylidenemethyl)-1,3-dihydroindol-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperidinyl/piperazinylalkyl substituted benzoxazines as ligands for 5-HT1A, 5-HT1B and 5-HT1D receptors and uses thereof)
RN 583031-25-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-6-(4-piperidinylidenemethyl)- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 5

L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:490721 CAPLUS
DN 141:54192
TI Preparation of aminoalkoxyindoles as 5-HT6-receptor ligands, in particular selective 5-HT6 antagonists, for treating CNS disorders
IN Zhao, Shu-Hai
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050085	A1	20040617	WO 2003-EP13372	20031127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA	2508315	A1	20040617	CA 2003-2508315	20031127
AU	2003289903	A1	20040623	AU 2003-289903	20031127
AU	2003289903	B2	20080626		
EP	1569638	A1	20050907	EP 2003-782240	20031127
EP	1569638	B1	20070905		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR	2003016962	A	20051025	BR 2003-16962	20031127
CN	1713908	A	20051228	CN 2003-80104019	20031127
JP	2006509777	T	20060323	JP 2004-556206	20031127
NZ	539950	A	20070531	NZ 2003-539950	20031127
TW	284124	B	20070721	TW 2003-92133339	20031127
AT	372113	T	20070915	AT 2003-782240	20031127
ES	2291722	T3	20080301	ES 2003-782240	20031127
RU	2350602	C2	20090327	RU 2005-121125	20031127
US	20040132799	A1	20040708	US 2003-724683	20031201
US	7084169	B2	20060801		
ZA	2005004412	A	20060426	ZA 2005-4412	20050530
MX	2005005790	A	20051018	MX 2005-5790	20050531
IN	2005CN01106	A	20070720	IN 2005-CN1106	20050602
KR	755580	B1	20070906	KR 2005-710127	20050603
PRAI	US 2002-430506P	P	20021203		
	WO 2003-EP13372	W	20031127		

OS MARPAT 141:54192

IT 706783-81-5P, 3-Benzenesulfonyl-7-(piperidin-4-yloxy)-1H-indole monohydrochloride 706784-50-1P, 3-Benzenesulfonyl-7-(piperidin-4-yloxy)-1H-indole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(5-HT6 antagonist; preparation of aminoalkoxyindoles as 5-HT6-receptor ligands, in particular selective 5-HT6 antagonists, for treating CNS disorders)

RN 706783-81-5 CAPLUS

CN 1H-Indole, 3-(phenylsulfonyl)-7-(4-piperidinyloxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 706784-50-1 CAPLUS
CN 1H-Indole, 3-(phenylsulfonyl)-7-(4-piperidinyloxy)- (CA INDEX NAME)



IT 706784-12-5P, 4-[[3-(Benzenesulfanyl)-1H-indol-7-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester 706784-15-8P, 4-[[3-(Benzenesulfonyl)-1H-indol-7-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of aminoalkoxyindoles as 5-HT6-receptor ligands, in particular selective 5-HT6 antagonists, for treating CNS disorders)
RN 706784-12-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-(phenylthio)-1H-indol-7-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 706784-15-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-(phenylsulfonyl)-1H-indol-7-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 4

L8 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:979638 CAPLUS
DN 143:286283
TI Preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists
IN Heinrich, Timo; Boettcher, Henning; Leibrock, Joachim
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082886	A1	20050909	WO 2005-EP1446	20050214

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 102004010132 A1 20050915 DE 2004-102004010132 20040227
AU 2005217043 A1 20050909 AU 2005-217043 20050214
CA 2557489 A1 20050909 CA 2005-2557489 20050214
EP 1718634 A1 20061108 EP 2005-715322 20050214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
JP 2007523930 T 20070823 JP 2007-500098 20050214
US 20070197596 A1 20070823 US 2006-590912 20060828
PRAI DE 2004-102004010132 A 20040227
WO 2005-EP1446 W 20050214
OS MARPAT 143:286283
IT 1066560-13-1 1066560-14-2 1066560-15-3
1066560-16-4 1066560-17-5 1066560-18-6
1066560-19-7 1066560-20-0 1066560-21-1
1066560-22-2 1066560-23-3 1066560-24-4
1066560-25-5 1066560-26-6 1066560-27-7
1066560-28-8 1066560-29-9 1066560-30-2
1066560-31-3 1066560-32-4 1066560-33-5
1066560-34-6
RL: PRPH (Prophetic)
(Preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists)
RN 1066560-13-1 CAPLUS
CN Cyanic acid, 7-[(dimethylamino)[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methyl]-2,3-dihydro-1H-indol-3-yl ester (CA INDEX NAME)



RN 1066560-14-2 CAPLUS
CN Cyanic acid, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]-2,3-dihydro-1H-indol-3-yl ester (CA INDEX NAME)



RN 1066560-15-3 CAPLUS
CN Benzonitrile, 4-[2-[4-[amino(3-fluoro-2,3-dihydro-1H-indol-7-yl)methyl]-1-piperidinyl]ethyl]- (CA INDEX NAME)



RN 1066560-16-4 CAPLUS
CN Cyanic acid, 7-[[1-[2-(4-cyanophenyl)ethyl]-4-piperidinyl]hydroxymethyl]-2,3-dihydro-1H-indol-3-yl ester (CA INDEX NAME)



RN 1066560-17-5 CAPLUS
CN Cyanic acid, 7-[[1-[2-(4-cyanophenyl)ethyl]-4-piperidinyl](dimethylamino)methyl]-2,3-dihydro-1H-indol-3-yl ester (CA INDEX NAME)



RN 1066560-18-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A

RN 1066560-19-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A

RN 1066560-20-0 CAPLUS
CN Benzonitrile, 4-[2-[4-[[2,3-dihydro-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl](dimethylamino)methyl]-1-piperidinyl]ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1066560-21-1 CAPLUS
CN 1H-Indole-7-methanol, 3-fluoro-α-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]- (CA INDEX NAME)



RN 1066560-22-2 CAPLUS
CN 1H-Indole-7-methanamine, 3-fluoro-α-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]- (CA INDEX NAME)



RN 1066560-23-3 CAPLUS
CN Cyanic acid, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]-1H-indol-3-yl ester (CA INDEX NAME)



RN 1066560-24-4 CAPLUS
CN Cyanic acid, 7-[(dimethylamino)[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methyl]-1H-indol-3-yl ester (CA INDEX NAME)



RN 1066560-25-5 CAPLUS
CN Benzonitrile, 4-[2-[4-[(3-fluoro-1H-indol-7-yl)hydroxymethyl]-1-piperidinyl]ethyl]- (CA INDEX NAME)



RN 1066560-26-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1066560-27-7 CAPLUS
CN Cyanic acid, 7-[[1-[2-(4-cyanophenyl)ethyl]-4-piperidinyl]hydroxymethyl]-1H-indol-3-yl ester (CA INDEX NAME)



RN 1066560-28-8 CAPLUS
CN Cyanic acid, 7-[[1-[2-(4-cyanophenyl)ethyl]-4-piperidinyl](dimethylamino)methyl]-1H-indol-3-yl ester (CA INDEX NAME)



RN 1066560-29-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A

RN 1066560-30-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A

RN 1066560-31-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A

RN 1066560-32-4 CAPLUS
CN 1H-Indole-7-methanol, 3-fluoro-α-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro- (CA INDEX NAME)



RN 1066560-33-5 CAPLUS
CN 1H-Indole-7-methanamine, 3-fluoro-α-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro- (CA INDEX NAME)



RN 1066560-34-6 CAPLUS
CN Benzonitrile, 4-[2-[4-[(3-fluoro-2,3-dihydro-1H-indol-7-yl)hydroxymethyl]-1-piperidinyl]ethyl]- (CA INDEX NAME)



IT 864297-53-0P 864297-54-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists)
RN 864297-53-0 CAPLUS
CN 1H-Indole-7-methanol, α-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]- (CA INDEX NAME)



RN 864297-54-1 CAPLUS
CN Methanone, [1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-1H-indol-7-yl- (CA INDEX NAME)



IT 864297-55-2P 864297-56-3P 864297-57-4P
864297-58-5P 864297-59-6P 864297-60-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists)
RN 864297-55-2 CAPLUS
CN 1H-Indole-3-carbonitrile, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]carbonyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 864297-56-3 CAPLUS
CN 1H-Indole-7-methanol, α-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-

2,3-dihydro- (CA INDEX NAME)



RN 864297-57-4 CAPLUS
CN Ethanone, 2,2,2-trifluoro-1-[7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]-1H-indol-3-yl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 864297-58-5 CAPLUS
CN Ethanone, 1-[7-[(dimethylamino)[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methyl]-1H-indol-3-yl]-2,2,2-trifluoro- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 864297-59-6 CAPLUS
CN 1H-Indole-3-carbonitrile, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]- (CA INDEX NAME)



RN 864297-60-9 CAPLUS
CN 1H-Indole-3-carbonitrile, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]carbonyl]- (CA INDEX NAME)



IT 864297-61-0 864297-62-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists)
RN 864297-61-0 CAPLUS
CN 1H-Indole-7-methanol, α-4-piperidinyl- (CA INDEX NAME)



RN 864297-62-1 CAPLUS
CN 1H-Indole-7-methanol, 2,3-dihydro-α-4-piperidinyl- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 3

L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:198079 CAPLUS
DN 144:362583
TI 1-(1-Phenethylpiperidin-4-yl)-1-phenylethanols as potent and highly selective 5-HT2A antagonists
AU Heinrich, Timo; Boettcher, Henning; Pruecher, Helmut; Gottschlich, Rudolf; Ackermann, Karl-August; van Amsterdam, Christoph
CS Preclinical Pharmaceutical Research, Merck KGaA, Darmstadt, 64293, Germany
SO ChemMedChem (2006), 1(2), 245-255
CODEN: CHEMGX; ISSN: 1860-7179
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
IT 864297-53-0 864297-54-1 864297-56-3
864297-57-4 864297-59-6 864297-60-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and structure activity relations of (phenethylpiperidinyl)phenylethanols as potent and highly selective 5-HT2A antagonists)
RN 864297-53-0 CAPLUS
CN 1H-Indole-7-methanol, α-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]- (CA INDEX NAME)



RN 864297-54-1 CAPLUS
CN Methanone, [1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-1H-indol-7-yl- (CA INDEX NAME)



RN 864297-56-3 CAPLUS
CN 1H-Indole-7-methanol, α-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-2,3-dihydro- (CA INDEX NAME)



RN 864297-57-4 CAPLUS
CN Ethanone, 2,2,2-trifluoro-1-[7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]-1H-indol-3-yl]- (CA INDEX NAME)

PAGE 1-A



RN 864297-59-6 CAPLUS
CN 1H-Indole-3-carbonitrile, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]hydroxymethyl]- (CA INDEX NAME)



RN 864297-60-9 CAPLUS
CN 1H-Indole-3-carbonitrile, 7-[[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]carbonyl]- (CA INDEX NAME)



IT 864297-62-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and structure activity relations of (phenethylpiperidinyl)phenylethanols as potent and highly selective 5-HT2A antagonists)
RN 864297-62-1 CAPLUS
CN 1H-Indole-7-methanol, 2,3-dihydro-α-4-piperidinyl- (CA INDEX NAME)



RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 2

L8 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:1356517 CAPLUS
DN 148:92237
TI New Serotonin 5-HT6 Ligands from Common Feature Pharmacophore Hypotheses
AU Kim, Hye-Jung; Doddareddy, Munikumar Reddy; Choo, Hyunah; Cho, Yong Seo; No, Kyoung Tai; Park, Woo-Kyu; Pae, Ae Nim
CS Life Science Division, Korea Institute of Science and Technology, Seoul, 130-650, S. Korea

SO Journal of Chemical Information and Modeling (2008), 48(1), 197-206
CODEN: JCISD8; ISSN: 1549-9596
PB American Chemical Society
DT Journal
LA English
IT 1000170-74-0
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug design, structure-activity profile and a sequential virtual screening procedure for new serotonin 5-HT6 ligands from common feature pharmacophore hypotheses)
RN 1000170-74-0 CAPLUS
CN Benzenesulfonamide, N-[7-[[(2R,4S)-2-fluoro-4-piperidinyl]methyl]-1H-indol-5-yl]-2-methoxy-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 1

L8 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:336963 CAPLUS
DN 150:329617
TI Substituted indolyl compounds as 5-HT6 ligands and their preparation, and use in the treatment of diseases
IN Ramakrishna, Nirogi Venkata Satya; Shinde, Anil Karbhari; Kambhampati, Rama Sastri; Jasti, Venkateswarlu
PA Suven Life Sciences Limited, India
SO PCT Int. Appl., 64pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2009034581	A1	20090319	WO 2008-IN280	20080502

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI IN 2007-CH2030 A 20070911

OS MARPAT 150:329617

IT 1131452-43-1P 1131452-44-2P 1131452-45-3P
1131452-46-4P 1131452-47-5P 1131452-48-6P
1131452-49-7P 1131452-50-0P 1131452-51-1P
1131452-52-2P 1131452-53-3P 1131452-54-4P
1131452-55-5P 1131452-56-6P 1131452-57-7P
1131452-58-8P 1131452-59-9P 1131452-60-2P
1131452-62-4P 1131452-63-5P 1131452-64-6P
1131452-65-7P 1131452-66-8P 1131452-67-9P
1131452-68-0P 1131452-69-1P 1131452-70-4P
1131452-71-5P 1131452-72-6P 1131452-73-7P
1131452-74-8P 1131452-75-9P 1131452-76-0P
1131452-77-1P 1131452-78-2P 1131452-79-3P
1131452-80-6P 1131452-81-7P 1131452-82-8P
1131452-83-9P 1131452-84-0P 1131452-85-1P
1131452-86-2P 1131452-87-3P 1131452-88-4P
1131452-89-5P 1131452-90-8P 1131452-91-9P
1131452-92-0P 1131452-93-1P 1131452-94-2P
1131452-95-3P 1131452-96-4P 1131452-97-5P
1131452-98-6P 1131452-99-7P 1131453-00-3P
1131453-01-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of substituted indolyl compds. as 5-HT6 ligands
useful in the treatment of diseases)

RN 1131452-43-1 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)-
(CA INDEX NAME)



RN 1131452-44-2 CAPLUS

CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-4-piperidinyl-,
hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 1131452-45-3 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-methyl-N-4-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 1131452-46-4 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-ethyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-47-5 CAPLUS
CN 1H-Indol-4-amine, N-ethyl-1-[(4-methylphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-48-6 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-ethyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-49-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[(3-chlorophenyl)sulfonyl]-1H-indol-4-yl]methylamino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1131452-50-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[methyl[1-[[4-(1-methylethyl)phenyl]sulfonyl]-1H-indol-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1131452-51-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[(4-fluorophenyl)sulfonyl]-1H-indol-4-yl]methylamino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1131452-52-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[methyl[1-[[3-(trifluoromethyl)phenyl]sulfonyl]-1H-indol-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1131452-53-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[(3-chlorophenyl)sulfonyl]-1H-indol-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1131452-54-4 CAPLUS
CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-methyl-N-4-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 1131452-55-5 CAPLUS
CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-4-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 1131452-56-6 CAPLUS
CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)-
(CA INDEX NAME)



RN 1131452-57-7 CAPLUS
CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-methyl-N-4-piperidinyl-,
hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 1131452-58-8 CAPLUS
CN 1H-Indol-4-amine, N-methyl-1-[[4-(1-methylethyl)phenyl]sulfonyl]-N-4-piperidinyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 1131452-59-9 CAPLUS
CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 1131452-60-2 CAPLUS
CN 1H-Indol-4-amine, 1-[(2,5-dimethoxyphenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-62-4 CAPLUS
CN 1H-Indol-4-amine, N-methyl-1-[(4-methylphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-63-5 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-methyl-N-(1-methyl-4-

piperidinyl)- (CA INDEX NAME)



RN 1131452-64-6 CAPLUS
CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-65-7 CAPLUS
CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-66-8 CAPLUS
CN 1H-Indol-4-amine, N-methyl-N-(1-methyl-4-piperidinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 1131452-67-9 CAPLUS
CN 1H-Indol-4-amine, N-methyl-1-[[4-(1-methylethyl)phenyl]sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-68-0 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-69-1 CAPLUS
CN 1H-Indol-4-amine, 1-[(4-methoxyphenyl)sulfonyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-70-4 CAPLUS
CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-1-[(4-methylphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-71-5 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(cyclopropylmethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-72-6 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-(cyclopropylmethyl)-N-(1-

methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-73-7 CAPLUS
CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-1-[(4-fluorophenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-74-8 CAPLUS
CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(cyclopropylmethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-75-9 CAPLUS
CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-N-(1-methyl-4-piperidinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 1131452-76-0 CAPLUS
CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-1-[(4-methoxyphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-77-1 CAPLUS
CN 1H-Indol-4-amine, N-(cyclopropylmethyl)-1-[[4-(1-methylethyl)phenyl]sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-78-2 CAPLUS
CN 1H-Indol-4-amine, N-(1-methylethyl)-1-[(4-methylphenyl)sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-79-3 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-80-6 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-81-7 CAPLUS
CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-82-8 CAPLUS
CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-83-9 CAPLUS
CN 1H-Indol-4-amine, N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 1131452-84-0 CAPLUS

CN 1H-Indol-4-amine, 1-[(4-methoxyphenyl)sulfonyl]-N-(1-methylethyl)-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-85-1 CAPLUS
CN 1H-Indol-4-amine, N-(1-methylethyl)-1-[[4-(1-methylethyl)phenyl]sulfonyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-86-2 CAPLUS
CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidinyl)-1-[(4-methylphenyl)sulfonyl]-
(CA INDEX NAME)



RN 1131452-87-3 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(1-ethyl-4-piperidinyl)-
(CA INDEX NAME)



RN 1131452-88-4 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-(1-ethyl-4-piperidinyl)-
(CA INDEX NAME)



RN 1131452-89-5 CAPLUS
CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidinyl)-1-[(4-fluorophenyl)sulfonyl]-
(CA INDEX NAME)



RN 1131452-90-8 CAPLUS
CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(1-ethyl-4-piperidinyl)-
(CA INDEX NAME)



RN 1131452-91-9 CAPLUS
CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidinyl)-1-[[3-
(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 1131452-92-0 CAPLUS
CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidinyl)-1-[(4-methoxyphenyl)sulfonyl]-
(CA INDEX NAME)



RN 1131452-93-1 CAPLUS
CN 1H-Indol-4-amine, N-(1-ethyl-4-piperidinyl)-1-[[4-(1-methylethyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 1131452-94-2 CAPLUS
CN 1H-Indol-4-amine, 1-[(4-methylphenyl)sulfonyl]-N-(1-propyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-95-3 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-bromophenyl)sulfonyl]-N-(1-propyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131452-96-4 CAPLUS
CN 1H-Indol-4-amine, 1-[(2-chlorophenyl)sulfonyl]-N-(1-propyl-4-piperidinyl)-
(CA INDEX NAME)



RN 1131452-97-5 CAPLUS
CN 1H-Indol-4-amine, 1-[(4-fluorophenyl)sulfonyl]-N-(1-propyl-4-piperidinyl)-
(CA INDEX NAME)



RN 1131452-98-6 CAPLUS
CN 1H-Indol-4-amine, 1-[(3-chlorophenyl)sulfonyl]-N-(1-propyl-4-piperidinyl)-
(CA INDEX NAME)



RN 1131452-99-7 CAPLUS
CN 1H-Indol-4-amine, N-(1-propyl-4-piperidinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 1131453-00-3 CAPLUS
CN 1H-Indol-4-amine, 1-[(4-methoxyphenyl)sulfonyl]-N-(1-propyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131453-01-4 CAPLUS
CN 1H-Indol-4-amine, 1-[[4-(1-methylethyl)phenyl]sulfonyl]-N-(1-propyl-4-piperidinyl)- (CA INDEX NAME)



IT 1131453-02-5P 1131453-03-6P 1131453-04-7P
1131453-05-8P 1131453-06-9P 1131453-07-0P
1131453-11-6P 1131453-12-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted indolyl compds. as 5-HT6 ligands useful in the treatment of diseases)

RN 1131453-02-5 CAPLUS
CN 1H-Indol-4-amine, N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131453-03-6 CAPLUS
CN 1H-Indol-4-amine, N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 1131453-04-7 CAPLUS
CN 1H-Indol-4-amine, N-ethyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131453-05-8 CAPLUS
CN 1H-Indol-4-amine, N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 1131453-06-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-(1H-indol-4-ylmethylamino)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1131453-07-0 CAPLUS
CN 1H-Indol-4-amine, N-methyl-N-4-piperidinyl- (CA INDEX NAME)



RN 1131453-11-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[(2-bromophenyl)sulfonyl]-1H-indol-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1131453-12-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[(2-bromophenyl)sulfonyl]-1H-indol-4-yl]methylamino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    37.86     255.12

FILE 'REGISTRY' ENTERED AT 07:30:02 ON 28 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 MAY 2009  HIGHEST RN 1149431-57-1
DICTIONARY FILE UPDATES:  26 MAY 2009  HIGHEST RN 1149431-57-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s  1131453-03-6
L9            1 1131453-03-6
                (1131453-03-6/RN)

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.48     255.60

FILE 'CAPLUS' ENTERED AT 07:30:12 ON 28 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 28 May 2009  VOL 150 ISS 22
FILE LAST UPDATED: 27 May 2009  (20090527/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Feb 2009
```

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate

```
=> s l9
L10           1 L9

=> d bib abs hitstr

L10  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2009:336963  CAPLUS
DN   150:329617
TI   Substituted indolyl compounds as 5-HT6 ligands and their preparation, and
     use in the treatment of diseases
IN   Ramakrishna, Nirogi Venkata Satya; Shinde, Anil Karbhari; Kambhampati,
     Rama Sastri; Jasti, Venkateswarlu
PA   Suven Life Sciences Limited, India
SO   PCT Int. Appl., 64pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2009034581        A1    20090319    WO 2008-IN280           20080502
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRAI IN 2007-CH2030       A     20070911
OS   MARPAT 150:329617
GI
```



I



II

AB The invention relates to substituted indolyl compds. of formula I, their derivs., their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compns. containing them. Compds. of formula I wherein R is H, C1-3 alkyl, and C3-6 cycloalkyl; R1, R2 and R3 are independently H, halo, C1-3 (halo)alkyl, C3-6 cycloalkyl, and C1-3 (halo)alkoxy; R4 is H, C1-3 (halo)alkyl, aryl, aralkyl, C3-6 cycloalkyl and tert-butoxycarbonyl; m is 0 - 4; n and p are independently 0 - 5; are claimed. The invention also relates to a process for the preparation of above said compds., their derivs., their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compns. containing them. This invention also relates to the intermediates involved therein and process of their preparation These compds. are useful in the treatment of various disorders that are related to 5-HT6 receptor functions. Example compound II was prepared by reductive amination of 1-methylpiperidin-4-one with 4-amino-1-(2-bromophenylsulfonyl)-1H-indole. All the invention compds. were evaluated for their 5-HT6 modulatory activity. From the assay, it was determined that compound II exhibited Ki value of 17.9 nM.

IT 1131453-03-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted indolyl compds. as 5-HT6 ligands useful in the treatment of diseases)

RN 1131453-03-6 CAPLUS

CN 1H-Indol-4-amine, N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d l1
L1 HAS NO ANSWERS
L1                STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   9  10  17
NUMBER OF NODES IS  25

STEREO ATTRIBUTES: NONE


=> s l1 ful
FULL SEARCH INITIATED 10:21:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     9156 TO ITERATE

100.0% PROCESSED     9156 ITERATIONS                              30 ANSWERS
SEARCH TIME: 00.00.01

L3           30 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   187.80     188.52

FILE 'CAPLUS' ENTERED AT 10:21:37 ON 20 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 20 Jul 2009 VOL 151 ISS 4
FILE LAST UPDATED: 19 Jul 2009 (20090719/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases will soon be updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 22.

=> s l3
L4 2 L3

=> d bib abs 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:198079 CAPLUS
DN 144:362583
TI 1-(1-Phenethylpiperidin-4-yl)-1-phenylethanols as potent and highly selective 5-HT2A antagonists
AU Heinrich, Timo; Boettcher, Henning; Pruecher, Helmut; Gottschlich, Rudolf; Ackermann, Karl-August; van Amsterdam, Christoph
CS Preclinical Pharmaceutical Research, Merck KGaA, Darmstadt, 64293, Germany
SO ChemMedChem (2006), 1(2), 245-255
CODEN: CHEMGX; ISSN: 1860-7179
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
AB The discovery of a novel class of highly potent and selective 5-HT2A antagonists is reported herein. Selectivity for the serotonin 5-HT2A receptor was optimized, decreasing the affinity of these antagonists toward the adrenergic α1 and dopaminergic D2 receptors, and especially to the 5-HT2C receptor. A series of corresponding 7-substituted indoles is described for the first time as serotonergic ligands. The enantiomer R-(+)-1-(4-fluorophenyl)-1-{1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}ethanol was identified to have superior affinity for the serotonergic 5-HT2A receptor [IC50 = 0.37 nM] and selectivity toward the dopaminergic D2- [IC50 = 2300 nM], adrenergic α1- [IC50 = 1000 nM] and 5-HT2C receptors [IC50 = 490 nM].
RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:979638 CAPLUS
DN 143:286283
TI Preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists
IN Heinrich, Timo; Boettcher, Henning; Leibrock, Joachim
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082886	A1	20050909	WO 2005-EP1446	20050214
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004010132	A1	20050915	DE 2004-102004010132	20040227
	AU 2005217043	A1	20050909	AU 2005-217043	20050214
	CA 2557489	A1	20050909	CA 2005-2557489	20050214
	EP 1718634	A1	20061108	EP 2005-715322	20050214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	JP 2007523930	T	20070823	JP 2007-500098	20050214
	US 20070197596	A1	20070823	US 2006-590912	20060828
PRAI	DE 2004-102004010132	A	20040227		
	WO 2005-EP1446	W	20050214		

OS MARPAT 143:286283
GI



I II

III

AB Title compds. I [A = (R2)n; B = (X)m; X = H, halo, CN, etc.; Y = CHR2CHR2, CR2=CR2; Q = O, OH, NH, etc.; R1 = (un)substituted alkylcycloalkyl, alkylaryl, alkylheteroaryl; R2 = H, alkyl, alkylaryl; n, m = 1-3] and

their pharmaceutically acceptable salts and formulations were prepared For example, 4-fluorophenethyl mesylatealkylation of piperidine II afforded piperidinylmethylindole III. Compds. I are claimed to be 5-HT2a antagonists (no data provided).

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d l1
L1 HAS NO ANSWERS
L1                STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   9  10  17
NUMBER OF NODES IS  25

STEREO ATTRIBUTES: NONE


=> s l1 ful
FULL SEARCH INITIATED 10:21:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     9156 TO ITERATE

100.0% PROCESSED     9156 ITERATIONS                              30 ANSWERS
SEARCH TIME: 00.00.01

L3           30 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   187.80     188.52

FILE 'CAPLUS' ENTERED AT 10:21:37 ON 20 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 20 Jul 2009 VOL 151 ISS 4
FILE LAST UPDATED: 19 Jul 2009 (20090719/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases will soon be updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 22.

=> s l3
L4 2 L3

=> d bib abs 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:198079 CAPLUS
DN 144:362583
TI 1-(1-Phenethylpiperidin-4-yl)-1-phenylethanols as potent and highly selective 5-HT2A antagonists
AU Heinrich, Timo; Boettcher, Henning; Pruecher, Helmut; Gottschlich, Rudolf; Ackermann, Karl-August; van Amsterdam, Christoph
CS Preclinical Pharmaceutical Research, Merck KGaA, Darmstadt, 64293, Germany
SO ChemMedChem (2006), 1(2), 245-255
CODEN: CHEMGX; ISSN: 1860-7179
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
AB The discovery of a novel class of highly potent and selective 5-HT2A antagonists is reported herein. Selectivity for the serotonin 5-HT2A receptor was optimized, decreasing the affinity of these antagonists toward the adrenergic α1 and dopaminergic D2 receptors, and especially to the 5-HT2C receptor. A series of corresponding 7-substituted indoles is described for the first time as serotonergic ligands. The enantiomer R-(+)-1-(4-fluorophenyl)-1-{1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}ethanol was identified to have superior affinity for the serotonergic 5-HT2A receptor [IC50 = 0.37 nM] and selectivity toward the dopaminergic D2- [IC50 = 2300 nM], adrenergic α1- [IC50 = 1000 nM] and 5-HT2C receptors [IC50 = 490 nM].
RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:979638 CAPLUS
DN 143:286283
TI Preparation of 7-(4-piperidinylmethyl)indoles as potent 5-HT2a antagonists
IN Heinrich, Timo; Boettcher, Henning; Leibrock, Joachim
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082886	A1	20050909	WO 2005-EP1446	20050214
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004010132	A1	20050915	DE 2004-102004010132	20040227
	AU 2005217043	A1	20050909	AU 2005-217043	20050214
	CA 2557489	A1	20050909	CA 2005-2557489	20050214
	EP 1718634	A1	20061108	EP 2005-715322	20050214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	JP 2007523930	T	20070823	JP 2007-500098	20050214
	US 20070197596	A1	20070823	US 2006-590912	20060828
PRAI	DE 2004-102004010132	A	20040227		
	WO 2005-EP1446	W	20050214		

OS MARPAT 143:286283
GI



I II

III

AB Title compds. I [A = (R2)n; B = (X)m; X = H, halo, CN, etc.; Y = CHR2CHR2, CR2=CR2; Q = O, OH, NH, etc.; R1 = (un)substituted alkylcycloalkyl, alkylaryl, alkylheteroaryl; R2 = H, alkyl, alkylaryl; n, m = 1-3] and

their pharmaceutically acceptable salts and formulations were prepared For example, 4-fluorophenethyl mesylatealkylation of piperidine II afforded piperidinylmethylindole III. Compds. I are claimed to be 5-HT2a antagonists (no data provided).

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT